Kymera Therapeutics, Inc. (KYMR)


-0.66 (-3.10%)
Symbol KYMR
Price $20.61
Beta 1.664
Volume Avg. 0.69M
Market Cap 1.144B
Shares () -
52 Week Range 9.6-39.85
1y Target Est -
DCF Unlevered KYMR DCF ->
DCF Levered KYMR LDCF ->
ROE -36.41% Strong Sell
ROA -29.38% Sell
Operating Margin -
Debt / Equity 20.44% Neutral
P/E -7.21 Strong Sell
P/B 3.04 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest KYMR news

Dr. Nello Mainolfi M.D., Ph.D.
NASDAQ Global Market

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.